APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nivolumab Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nivolumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026183 pages

Choose your research edition.

Industry ResearchNivolumab Injection Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Nivolumab Injection Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Nivolumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nivolumab Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Nivolumab Injection Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Nivolumab Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Nivolumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nivolumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nivolumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nivolumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nivolumab Injection include Sinopharm, AbbVie, Ono Pharmaceutical, Bristol-Myers Squibb and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nivolumab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nivolumab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nivolumab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nivolumab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Nivolumab Injection Segment by Company

Sinopharm

AbbVie

Ono Pharmaceutical

Bristol-Myers Squibb

Allergan

Nivolumab Injection Segment by Type

100IU

50IU

Other

Nivolumab Injection Segment by Application

Metastatic Squamous NSCLC

Metastatic Melanoma

Renal Cell Carcinoma

Classical Hodgkin Lymphoma

Unresectable Melanoma

Other

Nivolumab Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nivolumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nivolumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nivolumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nivolumab Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nivolumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Nivolumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Nivolumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Nivolumab Injection Industry Trends Table 2. Nivolumab Injection Industry Drivers Table 3. Nivolumab Injection Industry Opportunities and Challenges Table 4. Nivolumab Injection Industry Restraints Table 5. Global Nivolumab Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Nivolumab Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Nivolumab Injection Sales by Manufacturers (Units) & (2021-2026) Table 8. Global Nivolumab Injection Sales Market Share by Manufacturers Table 9. Global Nivolumab Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Nivolumab Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Nivolumab Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Nivolumab Injection Manufacturers, Product Type & Application Table 13. Global Nivolumab Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Nivolumab Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 100IU Table 17. Major Manufacturers of 50IU Table 18. Major Manufacturers of Other Table 19. Global Nivolumab Injection Sales by Type 2021 VS 2025 VS 2032 (Units) Table 20. Global Nivolumab Injection Sales by Type (2021-2026) & (Units) Table 21. Global Nivolumab Injection Sales by Type (2027-2032) & (Units) Table 22. Global Nivolumab Injection Sales Market Share by Type (2021-2026) Table 23. Global Nivolumab Injection Sales Market Share by Type (2027-2032) Table 24. Global Nivolumab Injection Revenue by Type 2021 VS 2025 VS 2032 (Units) Table 25. Global Nivolumab Injection Revenue by Type (2021-2026) & (Units) Table 26. Global Nivolumab Injection Revenue by Type (2027-2032) & (Units) Table 27. Global Nivolumab Injection Revenue Market Share by Type (2021-2026) Table 28. Global Nivolumab Injection Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Metastatic Squamous NSCLC Table 30. Major Manufacturers of Metastatic Melanoma Table 31. Major Manufacturers of Renal Cell Carcinoma Table 32. Major Manufacturers of Classical Hodgkin Lymphoma Table 33. Major Manufacturers of Unresectable Melanoma Table 34. Major Manufacturers of Other Table 35. Global Nivolumab Injection Sales by Application 2021 VS 2025 VS 2032 (Units) Table 36. Global Nivolumab Injection Sales by Application (2021-2026) & (Units) Table 37. Global Nivolumab Injection Sales by Application (2027-2032) & (Units) Table 38. Global Nivolumab Injection Sales Market Share by Application (2021-2026) Table 39. Global Nivolumab Injection Sales Market Share by Application (2027-2032) Table 40. Global Nivolumab Injection Revenue by Application 2021 VS 2025 VS 2032 (Units) Table 41. Global Nivolumab Injection Revenue by Application (2021-2026) & (Units) Table 42. Global Nivolumab Injection Revenue by Application (2027-2032) & (Units) Table 43. Global Nivolumab Injection Revenue Market Share by Application (2021-2026) Table 44. Global Nivolumab Injection Revenue Market Share by Application (2027-2032) Table 45. Global Nivolumab Injection Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 46. Global Nivolumab Injection Sales by Region (2021-2026) & (Units) Table 47. Global Nivolumab Injection Sales Market Share by Region (2021-2026) Table 48. Global Nivolumab Injection Sales Forecasted by Region (2027-2032) & (Units) Table 49. Global Nivolumab Injection Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Nivolumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 51. North America Nivolumab Injection Sales by Country (2021-2026) & (Units) Table 52. North America Nivolumab Injection Sales by Country (2027-2032) & (Units) Table 53. Europe Nivolumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 54. Europe Nivolumab Injection Sales by Country (2021-2026) & (Units) Table 55. Europe Nivolumab Injection Sales by Country (2027-2032) & (Units) Table 56. Asia Pacific Nivolumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 57. Asia Pacific Nivolumab Injection Sales by Country (2021-2026) & (Units) Table 58. Asia Pacific Nivolumab Injection Sales by Country (2027-2032) & (Units) Table 59. South America, Middle East and Africa Nivolumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 60. South America, Middle East and Africa Nivolumab Injection Sales by Country (2021-2026) & (Units) Table 61. South America, Middle East and Africa Nivolumab Injection Sales by Country (2027-2032) & (Units) Table 62. Global Nivolumab Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Nivolumab Injection Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Nivolumab Injection Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Nivolumab Injection Revenue Market Share by Region (2021-2026) Table 66. Global Nivolumab Injection Revenue Market Share by Region (2027-2032) Table 67. Sinopharm Company Information Table 68. Sinopharm Business Overview Table 69. Sinopharm Nivolumab Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Sinopharm Nivolumab Injection Product Portfolio Table 71. Sinopharm Recent Development Table 72. AbbVie Company Information Table 73. AbbVie Business Overview Table 74. AbbVie Nivolumab Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. AbbVie Nivolumab Injection Product Portfolio Table 76. AbbVie Recent Development Table 77. Ono Pharmaceutical Company Information Table 78. Ono Pharmaceutical Business Overview Table 79. Ono Pharmaceutical Nivolumab Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Ono Pharmaceutical Nivolumab Injection Product Portfolio Table 81. Ono Pharmaceutical Recent Development Table 82. Bristol-Myers Squibb Company Information Table 83. Bristol-Myers Squibb Business Overview Table 84. Bristol-Myers Squibb Nivolumab Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Bristol-Myers Squibb Nivolumab Injection Product Portfolio Table 86. Bristol-Myers Squibb Recent Development Table 87. Allergan Company Information Table 88. Allergan Business Overview Table 89. Allergan Nivolumab Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Allergan Nivolumab Injection Product Portfolio Table 91. Allergan Recent Development Table 92. Key Raw Materials Table 93. Raw Materials Key Suppliers Table 94. Nivolumab Injection Distributors List Table 95. Nivolumab Injection Customers List Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Nivolumab Injection Product Image Figure 2. Global Nivolumab Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nivolumab Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Nivolumab Injection Sales (2021-2032) & (Units) Figure 5. Global Nivolumab Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Nivolumab Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 100IU Image Figure 9. 50IU Image Figure 10. Other Image Figure 11. Global Nivolumab Injection Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 12. Global Nivolumab Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Nivolumab Injection Sales Market Share by Type (2021-2032) Figure 14. Global Nivolumab Injection Revenue by Type (2021 VS 2025 VS 2032) & (Units) Figure 15. Global Nivolumab Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Nivolumab Injection Revenue Market Share by Type (2021-2032) Figure 17. Metastatic Squamous NSCLC Image Figure 18. Metastatic Melanoma Image Figure 19. Renal Cell Carcinoma Image Figure 20. Classical Hodgkin Lymphoma Image Figure 21. Unresectable Melanoma Image Figure 22. Other Image Figure 23. Global Nivolumab Injection Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 24. Global Nivolumab Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Nivolumab Injection Sales Market Share by Application (2021-2032) Figure 26. Global Nivolumab Injection Revenue by Application (2021 VS 2025 VS 2032) & (Units) Figure 27. Global Nivolumab Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Nivolumab Injection Revenue Market Share by Application (2021-2032) Figure 29. North America Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 30. North America Nivolumab Injection Sales Market Share by Country (2021-2032) Figure 31. U.S. Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 32. Canada Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 33. Mexico Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 34. Europe Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 35. Europe Nivolumab Injection Sales Market Share by Country (2021-2032) Figure 36. Germany Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 37. France Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 38. U.K. Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 39. Italy Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 40. Netherlands Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 41. Asia Pacific Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 42. Asia Pacific Nivolumab Injection Sales Market Share by Country (2021-2032) Figure 43. China Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 44. Japan Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 45. South Korea Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 46. Southeast Asia Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 47. India Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 48. Australia Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 49. South America, Middle East and Africa Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 50. South America, Middle East and Africa Nivolumab Injection Sales Market Share by Country (2021-2032) Figure 51. Brazil Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 52. South Africa Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 53. Saudi Arabia Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 54. Turkey Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 55. Argentina Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 56. UAE Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 57. Egypt Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 58. Chile Nivolumab Injection Sales and Growth Rate (2021-2032) & (Units) Figure 59. Global Nivolumab Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Nivolumab Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Nivolumab Injection Revenue (2021-2032) & (US$ Million) Figure 62. North America Nivolumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Nivolumab Injection Revenue (2021-2032) & (US$ Million) Figure 64. Europe Nivolumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Nivolumab Injection Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Nivolumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Nivolumab Injection Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Nivolumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Nivolumab Injection Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Nivolumab Injection Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • 100IU
  • 50IU
  • Other
Applications
  • Metastatic Squamous NSCLC
  • Metastatic Melanoma
  • Renal Cell Carcinoma
  • Classical Hodgkin Lymphoma
  • Unresectable Melanoma
  • Other
Companies covered
  • Sinopharm
  • AbbVie
  • Ono Pharmaceutical
  • Bristol-Myers Squibb
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nivolumab Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nivolumab Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Nivolumab Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Nivolumab Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Nivolumab Injection Market Dynamics
  1. 2.1 Nivolumab Injection Industry Trends
  2. 2.2 Nivolumab Injection Industry Drivers
  3. 2.3 Nivolumab Injection Industry Opportunities and Challenges
  4. 2.4 Nivolumab Injection Industry Restraints
3 Nivolumab Injection Market by Manufacturers
  1. 3.1 Global Nivolumab Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Nivolumab Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Nivolumab Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Nivolumab Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nivolumab Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Nivolumab Injection Manufacturers, Product Type & Application
  7. 3.7 Global Nivolumab Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nivolumab Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nivolumab Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nivolumab Injection Tier 1, Tier 2, and Tier 3
4 Nivolumab Injection Market by Type
  1. 4.1 Nivolumab Injection Type Introduction
  2. 4.1.1 100IU
  3. 4.1.2 50IU
  4. 4.1.3 Other
  5. 4.2 Global Nivolumab Injection Sales by Type
  6. 4.2.1 Global Nivolumab Injection Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nivolumab Injection Sales by Type (2021-2032)
  8. 4.2.3 Global Nivolumab Injection Sales Market Share by Type (2021-2032)
  9. 4.3 Global Nivolumab Injection Revenue by Type
  10. 4.3.1 Global Nivolumab Injection Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Nivolumab Injection Revenue by Type (2021-2032)
  12. 4.3.3 Global Nivolumab Injection Revenue Market Share by Type (2021-2032)
5 Nivolumab Injection Market by Application
  1. 5.1 Nivolumab Injection Application Introduction
  2. 5.1.1 Metastatic Squamous NSCLC
  3. 5.1.2 Metastatic Melanoma
  4. 5.1.3 Renal Cell Carcinoma
  5. 5.1.4 Classical Hodgkin Lymphoma
  6. 5.1.5 Unresectable Melanoma
  7. 5.1.6 Other
  8. 5.2 Global Nivolumab Injection Sales by Application
  9. 5.2.1 Global Nivolumab Injection Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Nivolumab Injection Sales by Application (2021-2032)
  11. 5.2.3 Global Nivolumab Injection Sales Market Share by Application (2021-2032)
  12. 5.3 Global Nivolumab Injection Revenue by Application
  13. 5.3.1 Global Nivolumab Injection Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Nivolumab Injection Revenue by Application (2021-2032)
  15. 5.3.3 Global Nivolumab Injection Revenue Market Share by Application (2021-2032)
6 Global Nivolumab Injection Sales by Region
  1. 6.1 Global Nivolumab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nivolumab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Nivolumab Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Nivolumab Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nivolumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Nivolumab Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Nivolumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Nivolumab Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Nivolumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Nivolumab Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Nivolumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Nivolumab Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Nivolumab Injection Revenue by Region
  1. 7.1 Global Nivolumab Injection Revenue by Region
  2. 7.1.1 Global Nivolumab Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Nivolumab Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Nivolumab Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Nivolumab Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Nivolumab Injection Revenue (2021-2032)
  8. 7.2.2 North America Nivolumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Nivolumab Injection Revenue (2021-2032)
  11. 7.3.2 Europe Nivolumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Nivolumab Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Nivolumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Nivolumab Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Nivolumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sinopharm
  2. 8.1.1 Sinopharm Company Information
  3. 8.1.2 Sinopharm Business Overview
  4. 8.1.3 Sinopharm Nivolumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sinopharm Nivolumab Injection Product Portfolio
  6. 8.1.5 Sinopharm Recent Developments
  7. 8.2 AbbVie
  8. 8.2.1 AbbVie Company Information
  9. 8.2.2 AbbVie Business Overview
  10. 8.2.3 AbbVie Nivolumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Nivolumab Injection Product Portfolio
  12. 8.2.5 AbbVie Recent Developments
  13. 8.3 Ono Pharmaceutical
  14. 8.3.1 Ono Pharmaceutical Company Information
  15. 8.3.2 Ono Pharmaceutical Business Overview
  16. 8.3.3 Ono Pharmaceutical Nivolumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ono Pharmaceutical Nivolumab Injection Product Portfolio
  18. 8.3.5 Ono Pharmaceutical Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Nivolumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Nivolumab Injection Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Allergan
  26. 8.5.1 Allergan Company Information
  27. 8.5.2 Allergan Business Overview
  28. 8.5.3 Allergan Nivolumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Allergan Nivolumab Injection Product Portfolio
  30. 8.5.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nivolumab Injection Value Chain Analysis
  2. 9.1.1 Nivolumab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nivolumab Injection Production Mode & Process
  6. 9.2 Nivolumab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nivolumab Injection Distributors
  9. 9.2.3 Nivolumab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst